glp-2 vs glp-1 Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes GLP-1 vs. GLP-2 vs. GLP-3:

Syringes remain a common method of insulin delivery

Due to their buzz on social media, GlobalData anticipates that they will be among the top-selling medications in 2024, contributing to an expected increase to $150 billion by 2032

NICHOLAS P ALVAREZ (Chief Acquisition Officer) sold 75,000 shares for an estimated $443,760 ERIC HAROLD YECIES (Chief Legal Officer & GC) sold 15,000 shares for an estimated $183,750 To track insider transactions, check out Quiver Quantitative's insider trading dashboard

sentiment around affordability of GLP-1 medications, highlighting why patients increasingly seek compounded alternatives